Pancreatic Cancer Research

ResearcherThe University of SydneyNo recent work listed

Ross C. Smith

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8132-9024; OpenAlex author ID A5105298194. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: 2 papers

Papers 8

  1. Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. Co-author DOI 10.1002/cplu.202000253↗
  2. Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in … Co-author DOI 10.1016/j.canlet.2020.08.045↗
  3. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.neo.2016.06.001↗
  4. Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. Last author DOI 10.1371/journal.pone.0151475↗
  5. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Co-author DOI 10.1158/1078-0432.ccr-14-0365↗
  6. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-13-3377↗
  7. Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS. Last author DOI 10.1016/j.pan.2012.02.009↗
  8. Targeted alpha therapy approach to the management of pancreatic cancer. Last author DOI 10.3390/cancers3021821↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aiqun Xue · 6 shared papers, 2012–2020 · strength 0.43
  2. Sohel M. Julovi · 4 shared papers, 2014–2020 · strength 0.32
  3. Jerikho C. Bulanadi · 3 shared papers, 2016–2020 · strength 0.28
  4. Minoo J. Moghaddam · 3 shared papers, 2016–2020 · strength 0.28
  5. Anthony James Gill · 3 shared papers, 2014–2020 · strength 0.20
  6. Nick Pavlakis · 2 shared papers, 2014–2016 · strength 0.12
  7. Matthew H. Wong · 2 shared papers, 2014–2016 · strength 0.12
  8. Jaswinder Singh Samra · 1 shared paper, 2014 · strength 0.04
  9. Claire Jenkinson · 1 shared paper, 2015 · strength 0.04
  10. Alexey A. Zaikin · 1 shared paper, 2015 · strength 0.04
  11. Darragh Patrick O'Brien · 1 shared paper, 2015 · strength 0.04
  12. Stephen P. Pereira · 1 shared paper, 2015 · strength 0.04
  13. John F. Timms · 1 shared paper, 2015 · strength 0.04
  14. Oleg B. Blyuss · 1 shared paper, 2015 · strength 0.04
  15. Eithne Costello · 1 shared paper, 2015 · strength 0.04
  16. Robert C. Gandy · 1 shared paper, 2012 · strength 0.04
  17. Barry Allen · 1 shared paper, 2011 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.